PMID: 11907639Mar 22, 2002Paper

Myocardial bradykinin following acute angiotensin-converting enzyme inhibition, AT1 receptor blockade, or combined inhibition in congestive heart failure

Journal of Cardiovascular Pharmacology and Therapeutics
M M MultaniF G Spinale

Abstract

The present study examined the effects of acute angiotensin-converting enzyme inhibition (ACEI), AT(1) receptor blockade (AT(1) block), or combined treatment on in vitro and in vivo bradykinin (BK) levels. BK levels were measured in isolated porcine myocyte preparations (n = 13) in the presence of exogenous BK (10(-8) M); with an ACEI (benezaprilat; 0.1 mM) and BK; an AT(1) block (valsartan; 10(-5) M) and BK; and combined treatment and BK. In a second study, myocardial microdialysis was used to measure porcine interstitial BK levels in both normal (n = 14) and pacing-induced congestive heart failure (CHF) (240 beats/min, 3 weeks, n = 16) under the following conditions: baseline, following ACEI (benezaprilat, 0.0625 mg/kg) or AT(1) block (valsartan, 0.1 mg/kg), and a combined treatment (benezaprilat, 0.0625 mg/kg; valsartan, 0.1 mg/kg). In the left ventricular myocyte study, BK levels increased over 93% with all treatments compared to untreated values (P < 0.05). In the in vivo study, basal interstitial BK values were lower in the CHF group than in controls (2.64 +/- 0.57 vs 5.91 +/- 1.4 nM, respectively, P < 0.05). Following acute infusion of the ACEI, BK levels in the CHF state increased from baseline (57% +/- 22; P < 0.05). F...Continue Reading

References

Nov 30, 1990·Biochemical and Biophysical Research Communications·H RoggM de Gasparo
Sep 1, 1984·Annals of Internal Medicine·G S FrancisJ N Cohn
Jan 1, 1995·Journal of Molecular and Cellular Cardiology·M BrinkG Bullock
Oct 1, 1993·American Journal of Hypertension·H M SiragyH S Margolius
Feb 1, 1993·British Journal of Pharmacology·C R BaumgartenG Wiemer
Nov 1, 1995·European Heart Journal·F Cosentino, T F Lüscher
Nov 12, 1996·Biochemical and Biophysical Research Communications·Y OzawaH Miyazaki
Dec 24, 1997·British Journal of Pharmacology·A DendorferP Dominiak
Dec 2, 1998·Basic Research in Cardiology·V Regitz-ZagrosekE Fleck
Jul 23, 1999·Annals of the New York Academy of Sciences·M SatoR M Engelman
Oct 8, 1999·The Journal of Clinical Investigation·Y TsutsumiT Iwasaka
Dec 11, 1999·Circulation·L J Dell'Italia, S Oparil
Jan 1, 2000·Cardiovascular Research·K C Wollert, H Drexler
Feb 1, 2000·Trends in Endocrinology and Metabolism : TEM·S Nouet, C Nahmias
Mar 11, 2000·American Journal of Hypertension·A M AllenF A Mendelsohn
Jun 14, 2000·American Journal of Physiology. Heart and Circulatory Physiology·A ErgulF G Spinale

❮ Previous
Next ❯

Citations

Aug 2, 2005·European Journal of Pharmacology·Pedro MonteiroLuís A Providência
Jul 1, 2008·Pharmacology & Therapeutics·Daphne MerkusDirk J Duncker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.